Methylmalonic Acidemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Methylmalonic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions.
Methylmalonic Acidemia is an inborn or inherited metabolic disease where the levels of MMA (methylmalonic acid) are elevated in blood and urine. Deficiency in MMA Defect in conversion of methylmalonyl-coenzyme A (CoA) to succinyl-CoA causes accumulation of methylmalonyl-CoA and other potentially toxic compounds. It can be mild to severe appearing in early stages of life or in later stages. Seizures, encephalopathy and stroke are the neurological complication associated and if left untreated leads to coma and death. Vomiting’s, dehydration, lethargy, are other symptoms. Molecular genetic testing is a diagnostic method to find out the mutations on the gene. Protein restricted diet, high calorie diet followed by vitamin B12 supplementation, antibiotics and organ transplantation are other strategies.
The Methylmalonic Acidemia drugs in development market research report provide comprehensive information on the therapeutics under development for Methylmalonic Acidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methylmalonic Acidemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Methylmalonic Acidemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Methylmalonic Acidemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Methylmalonic Acidemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Methylmalonic Acidemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Agios Pharmaceuticals IncCoA Therapeutics Inc
Enlivex Therapeutics Ltd
HemoShear Therapeutics LLC
Imbria Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Logicbio Therapeutics Inc
Moderna Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Methylmalonic Acidemia reports